DF
NKTR icon

DecisionPoint Financial’s Nektar Therapeutics NKTR Stock Holding History

DecisionPoint Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-62
Closed -$2.11K – 216
2022
Q4 		$2.11K Buy
+62
New +$3K ﹤0.01% 146

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DecisionPoint Financial's NKTR Position: Q1 2023 in Review

DecisionPoint Financial sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 62 shares — an estimated $2.11K sold.

DecisionPoint Financial first reported a position in NKTR in Q4 2022 and held it in 1 quarter. The position peaked at $2.11K in Q4 2022. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

  • DecisionPoint Financial reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • DecisionPoint Financial sold 62 Nektar Therapeutics shares in Q1 2023, an estimated $2.11K.
  • DecisionPoint Financial first reported a position in Nektar Therapeutics in Q4 2022 and held it in 1 quarter.
  • DecisionPoint Financial's Nektar Therapeutics position peaked at $2.11K in Q4 2022.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on DecisionPoint Financial's 13F filing for Q1 2023, filed 26 Sep 2023.